



# City Research Online

## City, University of London Institutional Repository

---

**Citation:** Cooper, O., McBain, H. B. ORCID: 0000-0002-6742-1104, Tangayi, S., Telfer, P., Tsitsikas, D., Yardumian, A. and Mulligan, K. ORCID: 0000-0002-6003-3029 (2019). Psychometric Analysis of the Adult Sickle Cell Quality of Life Measurement Information System (ACSQ-Me) in a UK Population. Health and Quality of Life Outcomes,

This is the accepted version of the paper.

This version of the publication may differ from the final published version.

---

**Permanent repository link:** <http://openaccess.city.ac.uk/21948/>

**Link to published version:**

**Copyright and reuse:** City Research Online aims to make research outputs of City, University of London available to a wider audience. Copyright and Moral Rights remain with the author(s) and/or copyright holders. URLs from City Research Online may be freely distributed and linked to.

---

City Research Online:

<http://openaccess.city.ac.uk/>

[publications@city.ac.uk](mailto:publications@city.ac.uk)

---

**Full title: Psychometric Analysis of the Adult Sickle Cell Quality of Life Measurement Information System (ACSQ-Me) in a UK Population**

**Running short title: Validity and reliability of the ACSQ-Me in the UK**

**Authors:**

Owen Cooper<sup>1</sup>

Hayley McBain<sup>1</sup>

Sekayi Tangayi<sup>2</sup>

Paul Telfer<sup>3</sup>

Dimitris Tsitsikas<sup>4</sup>

Anne Yardumian<sup>5</sup>

Kathleen Mulligan, PhD<sup>1,2</sup>

<sup>1</sup>School of Health Sciences, City, University of London, London, UK

<sup>2</sup>East London NHS Foundation Trust, London, UK

<sup>3</sup>Barts Health NHS Trust

<sup>4</sup>Homerton University Hospital NHS Foundation Trust

<sup>5</sup>North Middlesex University Hospital

**Correspondence:**

Dr Kathleen Mulligan

School of Health Sciences

City, University of London

EC1V 0HB

United Kingdom

kathleen.mulligan.1@city.ac.uk

+44 (0)20 7040 0889

## **ABSTRACT**

### *Background*

The Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) has been shown to be a reliable and valid questionnaire measuring health-related quality of life (HRQoL) in the US sickle cell disease (SCD) population. The study objective was to test the validity and reliability of the ASCQ-Me for use in the UK.

### *Methods*

The US ASCQ-Me, Hospital Anxiety and Depression Scale (HADS), self-reported symptoms, and Medical Outcome Survey Short Form 36 (SF-36) were administered to 173 patients with SCD. Clinical severity was assessed by the number of painful episodes indicated by hospital admissions.

### *Results*

The results showed that the item banks of the UK ASCQ-Me had good internal consistency. Anxiety and depression were strongly correlated with the emotional, and social item banks of the UK ASCQ-Me, with moderate correlations between the UK ASCQ-Me item banks and SF-36 components suggesting convergent validity. A confirmatory factor analysis confirmed the conceptual framework of the scale as being the same as the US ASCQ-Me, indicating construct validity. Known groups validity was found, with the ASCQ-Me being able to differentiate by SCD severity groups.

### *Conclusion*

The analysis of the sample shows evidence of both validity and reliability of the ACCQ-Me for use in the UK SCD population.

### KEY WORDS

- Sickle Cell Disease; Quality of Life; ASCQ-Me; SF-36; Validity

## **BACKGROUND**

Sickle cell disease (SCD) is an inherited structural haemoglobin disorder, common in people whose family origins were from Africa, but also seen in people with family origins in the Eastern Mediterranean, Middle East and South Asia. In England, it is now the most common serious inherited disorder, with a birth prevalence of approximately 1 in 2000 [1]. There are three primary genotypes of SCD: haemoglobin SS (HbSS); haemoglobin SC (HbSC); and haemoglobin S $\beta$ -thalassaemia Hb (S $\beta$ Thal). An estimated 12,500 to 15,000 people in the UK have SCD [2].

SCD is one of the most common reasons for hospital admission and has the highest rate of multiple admissions for individual patients in the UK [3]. SCD has been found to adversely affect health-related quality of life (HRQoL), but there are few studies that have evaluated SCD HRQoL in adults in Europe. In a sample of 96 adults with SCD one study [4] found that HRQoL was significantly lower than that of the UK general population. To date, HRQoL has however, been assessed in adults with SCD using generic measures [5, 6], such as the RAND Medical Outcomes Study 36-item Short Form Survey (SF-36) [7] or EuroQol five-dimensional questionnaire (EQ-5D) [8]. Generic measures are required to enable comparison with other diseases as well as with the general population [9]. These measures, however, do have limitations as they do not measure the specific effects of the disease, and thus may not detect subtle, but clinically important variations in quality of life [10]. Disease-specific measures are likely to be more sensitive than generic measures to clinically significant change [11] as well as being more relevant to the disease under study [9].

HRQoL is an important outcome of clinical trials in SCD (Pecker et al, 2017), however there is currently no disease-specific HRQoL measure for adults with SCD that has been validated for

use in the UK [6]. Two disease-specific HRQoL measures have been developed and validated in the US: the Sickle Cell Impact Measurement Scale (SIMS) [12], and the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) [13, 14]. The SIMS was adapted from four existing questionnaires: the Arthritis Impact Measurement Scale (AIMS) [15] and three generic measures. It has four domains: pain; physical functioning; emotional well-being; social functioning. The SIMS validation study compared HRQoL in adults with SCD and rheumatoid arthritis (RA). No difference was found between the two patient groups on overall HRQoL but people with SCD scored higher than those with RA on physical and social domains [12]. The ASCQ-Me items were derived from research with adults who have SCD and their health care providers. It has been validated showing the item banks to be sensitive to SCD severity based on a self-reported medical history checklist, and validity has been shown utilising item response theory [16, 17]. It has been found that the ASCQ-Me also had similar discriminant validity to the Patient-Reported Outcomes Measurement Information System (PROMIS)[18] in regards to SCD severity [17]. Physical function, pain, and the ability to engage in social roles and activities, as measured by the ASCQ-Me, were most affected by SCD severity. All ASCQ-Me validation studies to date have been conducted in US samples. It is necessary to validate patient reported scales for use in their country, as definitions of quality of life are affected by national culture patterns [19, 20].

The study objective was to test the validity and reliability of the ASCQ-Me [13, 14] for use in the UK. This measure was chosen in preference to the SIMS, which consists of 142 items and was therefore considered too long to be practical by both clinicians and patients [12].

## **METHODS**

### *Study Design*

This was a cross-sectional study conducted at four National Health Service (NHS) hospitals in London.

### *Population*

Patients were invited to take part if they were adults aged  $\geq 18$  years, had a diagnosis of Sickle Cell Anaemia HbSS, Sickle C Disease HbSC or Sickle Beta Thalassaemia (Hb S $\beta$ Thal) and their haematologist considered them well enough to answer the ASCQ-Me (either assisted or unassisted)[21].

### *Data Collection*

Eligible patients were advised about the study by their haematologist when they attended a routine outpatient clinic appointment or, hospital day care unit . Once consented, participants were given a copy of the questionnaire which they could complete in clinic or take home and return in a postage-paid envelope.

### *Measures*

The questionnaire pack included:

- ASCQ-Me version 2.0 Short Form [14]. A 30-item measure with 7 item banks: Pain episode frequency (2 items); Pain episode severity (3 items); Pain impact (5 items); Emotional impact (5 items); Social impact (5 items); Stiffness (5 items); and Sleep impact (5 items). The latter five item banks are each scored from 5 (never) to 1 (always). Scores on each subscale are standardised to have a mean of 50 and a standard deviation of 10. A higher score represents better HRQoL on all item banks, apart from pain episode frequency and severity, on which higher scores indicate

greater frequency/severity. In the US, the ASCQ-Me has been shown to have excellent internal consistency for each item bank ( $\geq .90$ ) and the item banks differed significantly between SCD severity levels [16].

- The Medical Outcomes Study Short Form 36 (SF-36) [7] to assess generic HRQoL. The SF-36 is a 36-item measure with eight subscales: physical function; role limitation caused by physical function; pain; general health; energy/vitality; social function; role limitation caused by emotional difficulties; mental health. It also provides two composite scores for physical (PCS) and mental (MCS) HRQoL. Scores are transformed to a 0-100 scale on which the population mean is 50 and the standard deviation is 10. A higher score signifies better HRQoL. The SF-36 has previously shown to have good reliability and validity in the SCD population [22].
- Anxiety and depression were assessed with the Hospital Anxiety and Depression Scale (HADS) [23]. The HADS is a 14-item measure with individual scales for anxiety and depression. Each scale is scored from 0 – 21 with a higher score signifying greater anxiety or depression. A score of  $\geq 8$  indicates *possible* clinical depression/anxiety and a score of  $\geq 11$  indicates *probable* clinical depression/anxiety. The HADS has previously been validated in a clinical population [24], and been utilised in the UK SCD population [25].
- Symptoms: current pain, stiffness and fatigue were assessed with 10-point Visual Numeric Scales (VNS). Scores ranged from 0 to 10, with the higher scores indicating more pain, stiffness or fatigue [26].
- Number of days of college/work missed over the past month due to SCD, if applicable
- Current exercise tolerance: good, moderately reduced or severely reduced

- Number of painful crises managed at home during an average month/three month period over past two years

Routinely collected clinical data were extracted from participants' medical notes with their informed consent. This included:

- Genotype (HbSS, HbSC or Hb S $\beta$ Thal)
- Number of hospital admissions with pain crisis during past two years
- Acute chest syndrome: Number requiring transfusion over past 2 years
- History of:
  - Avascular necrosis (AVN) of hip
  - Stroke or recurrent transient ischemic attack (TIA)
  - Priapism
  - Severe, renal impairment: Requiring renal replacement treatment
  - History of Retinopathy with visual impairment
  - Elevated tricuspid regurgitation (TR) jet velocity
  - Catheter diagnosis of pulmonary hypertension
  - Recurrent ankle ulceration during past 2 years
  - Chronic pain: Persistent pain most days lasting more than 6 months
- Current medication with regular transfusion, medication with hydroxycarbamide, number of days of oral opioids used per week

Disease severity was classified based on the following criteria:

- People who have had  $\geq 3$  hospital admissions on average in the past 12 months vs those who have had  $< 3$  admissions on average.



These disease severity criteria are the standard for pain episodes and have previously been used as entry criteria for a trial of hydroxyurea (Charache, 1995).

### *Analysis*

Study data were analysed using IBM SPSS Statistics 23<sup>®</sup>. The significance level was set at  $p < 0.01$  in order to minimise the risk of a type I error. The pattern of missing data was evaluated using the missing data function. Any participant with more than 50% missing data was removed from the analysis. Little's Missing Completely At Random (MCAR) test was conducted to check if there were any systematic differences between the missing values and the observed values [27]. All analyses were carried out as instructed by a predetermined statistical analysis plan that detailed all planned analyses prior to data collection.

*Reliability.* Internal consistency was measured using Cronbach's alpha coefficient to test the degree to which items in each ASCQ-Me subscale were related to each other. There are no tests of statistical significance for these estimations, though alphas  $> 0.70$  are generally considered acceptable for aggregate data, with  $\geq 0.80$  to  $< 0.90$  indicating good consistency, and  $> 0.90$  excellent consistency [28].

*Validity.* Content validity, defined as the extent to which the instrument measures the concept of interest, was confirmed prior to data collection by obtaining the views of patients with SCD and experts working in SCD on the questionnaire items to ensure that they capture the different components of SCD HRQoL. Construct validity, defined as evidence that the relationship among items conform to a priori hypotheses, was tested by examining convergent and known groups validity [29]. Convergent validity assesses measures that have an expected logical relationship with each other. This was tested by

comparing the ASCQ-Me with the SF-36, HADS, and self-reported symptoms using Pearson's correlation coefficient. Known groups validity assesses the extent to which measures are able to distinguish differences and similarities between sub samples, this was tested by comparing groups expected to differ on ASCQ-Me subscales using an Independent sample t-tests or analysis of variance (ANOVA). Confirmatory factor analysis (CFA) of the ASCQ-Me was performed to examine the validity of the 5-factor structure. Further details of the analysis are included in the online supplementary material.

For correlation of convergent validity Pearson's R values of <0.20 are considered a very weak correlation,  $\geq 0.20$  to <0.40 a weak correlation,  $\geq 0.40$  to <0.60 moderate,  $\geq 0.60$  to <0.80 strong, and >0.80 a very strong correlation [30].

Known groups validity was tested using independent sample t-tests or analysis of variance (ANOVA) tests that were used to compare the means between groups. Scores were compared between:

- People with different types of SCD - HbSS, HbSC, and Hb S $\beta$ Thal.
- People who have an average of  $\geq 3$  hospital admissions per year over the past 2 years vs <3 hospital admissions

The fit of the CFA model was assessed with comparative fit index (CFI), and root mean square error of approximation (RMSEA). CFI greater than 0.90 was considered an acceptable fit, and RMSEA <0.07. RMSEA and CFI are standard statistical tests in CFA that assess the goodness of fit, this assesses how well the model-implied relationships of the items and the item banks are equivalent to the relationships in the sample data [31]. CFA was run using IBM® SPSS Statistics 23® AMOS 25.0. The standardized regression weights outputted in the CFA (Table 4) allow us to compare the means of individual items to the mean of each item bank in order to assess accuracy of fit of each item bank.

## RESULTS

### *Socio-Demographic & Clinical Details*

A total of 224 patients consented to the study, of which 173 (77.2%) completed and returned the questionnaire. Sociodemographic details of the sample analysed are shown in Table 1. The sample had an average age of 36 years (range 18-78 years), were mostly women (57.8%) and the vast majority indicated that they were either black or black British (93.0%).

The clinical characteristics of the sample are reported in Table 2. Patients were mostly HbSS (72.3%), 20.8% with a HbSC diagnosis and a smaller number Hb S $\beta$ Thal (4.0%). The number of transfusions used to treat acute chest syndrome over the previous 2 years was 0.7 (2.3). The results showed that the majority of participants had at least one pain crises per month on average (72.8%).

Scores on the SF-36 indicated impaired HRQoL; the physical composite score was more than one standard deviation (SD) below the standardised norm and the mental composite score was half a SD below. In reviewing the ASCQ-Me standardised scores for each item bank, the worst quality of life scores were seen in the social functioning item bank with a mean (SD) of 14.43 (5.22), followed by sleep 15.49 (4.67). Although HADS mean scores were in the normal range, HADS scores show that 46% of participants scored above the level for possible clinical anxiety and 41% for possible depression (Table 3). For 88% of the sample, their last pain attack had interfered with some aspect of their life and for 47% had lasted for 4 days or more.

### *Reliability*

Cronbach's alpha for the five primary ASCQ-Me item banks indicated that the sleep impact item bank had acceptable consistency (0.78), with the remaining 4 item banks showing excellent consistency (0.92-0.96).

### *Construct Validity*

The CFA (Table 4) was assessed with the model fit indices comparative fit index (CFI), and root mean square error of approximation (RMSEA). All but one of the items loaded to their item respective bank (shown by a standardised regression weight of  $>0.40$ ). The CFI met the minimum criteria for acceptable fit at 0.94, the RMSEA marginally exceeded the threshold of  $<0.07$  at 0.08. The item "How often was it very easy for you to fall asleep?" did not load to the Sleep factor ( $<0.40$ ), therefore it was removed from the model.

### *Convergent Validity*

All correlations between ASCQ-Me item banks and the SF-36 and HADS were shown to be statistically significant ( $p < 0.001$ ). For the HADS (Table 5), as expected, there was a strong relationship between the HADS anxiety and depression scales, and the emotional (Anxiety:  $r = -0.66$ , Depression:  $r = -0.64$ ), and social impact ASCQ-Me banks (Anxiety:  $r = -0.55$ , Depression:  $r = -0.58$ ). In reviewing the correlation between the ASCQ-Me item banks and SF-36 components, overall there were a number of moderate relationships. There was a stronger relationship between the ASCQ-Me pain item bank and the SF-36 physical component score (PCS,  $r = 0.52$ ), than with the pain item bank and the SF-36 mental component score (MCS,  $r = 0.37$ ). The emotional impact and social impact item banks of the ASCQ-Me had the strongest correlations with the mental component score of the SF-36 (Emotional:  $r = -0.68$ , Social:  $r = -0.61$ ).

### *Known Groups Validity*

There were no significant differences ( $p > 0.01$ ) between patients with HbSS, HbSC, or HbS $\beta$ Thal on any of the items banks (Table 6). Independent sample T-tests showed that all five of the ASCQ-Me item banks were able to significantly discriminate between a group of SCD patients that were admitted to the hospital three times or more on average in the previous 12 months compared to those that had been admitted twice or less ( $p < 0.01$ ).

In exploratory analysis of the previous medical history of the SCD patients it was found that there were significant differences on all of the ASCQ-Me item banks between patients who had a history of persistent pain most days lasting more than 6 months and those who did not ( $p < 0.001$ ) (Table S1). Furthermore, when reviewing medical history of avascular necrosis of hip (AVN), there were significant results for the stiffness ASCQ-Me item bank ( $p < 0.01$ ),

with patient that have had a history of AVN having lower scores indicating that they experience greater stiffness impact. There were no other significant results for any of the medical history items.

## **DISCUSSION**

The results and analyses in this study show strong evidence of validity and reliability for the ASCQ-Me to be used as a measure of disease-specific HRQoL in adults with SCD in the UK. All of the item banks had good internal consistency, with the majority being excellent, after removal of one sleep item. The CFA indicated that the conceptual framework of the item banks fitted well for each item, and with the US ASCQ-Me [16]. The RMSEA test of model fit did not meet the minimum threshold for acceptance, however these values were shown to be akin to other self-reported questionnaires with a similar number of items [32], and similar to that seen in Keller et al [16].

In reviewing the validity of the ASCQ-Me, the scale was compared with a generic QoL measure the SF-36, and the HADS. All ASCQ-Me item banks correlated significantly with the SF-36 subscales. As would be expected, the emotional impact item bank of the ASCQ-Me correlated more strongly with the SF-36 mental composite score than with the physical composite score, whereas the pain, stiffness and pain crisis frequency item banks correlated more strongly with the physical than the mental composite score. Sleep impact, social impact and pain crisis severity also correlated more strongly with the SF-36 physical than mental composite score, but only marginally. Anxiety and depression were strongly correlated with the emotional and social item banks of the ACSQ-Me, but weaker with the pain, sleep, and stiffness items. Although there is only a weak relationship between some item banks and the HADS, the stronger relationship between the HADS and the emotional

ASCQ-Me item bank is to be expected, due to the HADS probing patients on the emotions surrounding depression and anxiety. We can therefore argue that the ASCQ-Me has convergent validity.

In reviewing the known-groups validity data, the ASCQ-Me did not distinguish between SCD diagnoses, supporting previous work using generic HRQoL measures [22, 33, 34]. This does however, contrast with the systematic review of HRQoL in SCD by Panepinto and Bonner [6] that did report a difference between genotypes, however they did not provide specific details on the differences or of which study/ies reported this finding, making any further interpretation difficult. It should be noted however, that there were only seven participants of the sample with SβThal, indicating less reliability of the diagnoses known groups validity test. However, it is not uncommon for clinical indicators to not predict HRQoL; the relationship between disease severity in long-term conditions and HRQoL is not always a linear one [35]. Keller [17] stated that SCD genotypes, due to the broad variation of symptomatology, are an unreliable indicator of disease severity. However, previous literature has suggested HBSS have more severe symptoms [36-38]. The current study found that HBSS had the poorest HRQoL on the ASCQ-Me item banks in comparison to the other genotypes, although this was not statistically significant.

The ASCQ-Me was able to successfully distinguish between groups of patients that were frequently admitted to hospital compared to those that were not. As would be expected, the results showed that patients who were admitted to hospital more had poorer quality of life in all ASCQ-Me items banks. Poorer scores on the SF-36 physical component summary were associated with a greater number of visits to the emergency department in one study [39] but another found no relationship between SF-36 scores and hospital service use or

general practitioner visits [4]. The reason for these inconsistencies is most likely due to a number of factors, including clinical and socio-demographic differences between the samples, and a lack of reliable, valid, and consistent measurements of healthcare utilisation.

When compared to the ASCQ-Me field-test participants in Keller et al [16], our sample reported more pain crises during the past 12 months, but the duration of participants' most recent crisis, the percentage reporting that their last pain crisis interfered with their life and the level of pain severity experienced during the last pain crisis were very similar in the two samples. The current study also found that HRQoL in adults with SCD was impaired in relation to the general population, which confirms the findings of other research in this area. Anie, Steptoe, et al [4] used the SF-36 and found that HRQoL was significantly lower than that of the UK general population. Pain, and the use of affective coping strategies, defined as catastrophizing, anger and fearful self-statements, praying and hoping, and isolation, were associated with poorer HRQoL. The ASCQ-Me provides further insight into HRQoL specific to SCD that generic measures such as the SF-36 fail to measure. It was seen that sleep impact and stiffness were of importance to quality of life as they both correlated with the SF-36 PCS and MCS, and the HADS anxiety and depression scales. This shows the importance of using a disease-specific measure such as the ASCQ-Me to assess HRQoL in SCD patients.

Using the ASCQ-Me in clinical practice could provide useful information to healthcare providers. The tool is easy for patients to complete and for clinicians to interpret. It could be used to obtain reliable assessments at each clinic visit of several important issues for people with SCD including stiffness, sleep, pain, emotional, and social impact of SCD. Not all of these factors are routinely assessed however this study has shown that they are negatively



associated with the physical and mental well-being and therefore merit further attention in the clinical setting.

This study had a number of limitations. It could be argued that the SCD population was not representative of the UK general population as recruitment was only in London. This is also a limitation of other research that has examined HRQoL in people with SCD in the UK [4]. However, approximately two-thirds of people with SCD in the UK live in London with most others living in other large urban areas [41]. Although the analysis shows relationships between the measured variables, due to the limitations of correlation analysis, cause cannot be inferred. As some data were extracted from patients' medical notes, we acknowledge that there may be some inconsistencies in these data; this is an issue for all studies that extract data from medical notes.

Future studies could be carried out to provide further reliability and validity for the ASCQ-Me scale, this includes test-retest reliability. By measuring changes in severity mapped against changes in ASCQ-Me scores over time any clinical responsiveness of the scale would show further validity of the questionnaire. Such reliability and validity tests have so far not been carried out on the ASCQ-Me US version.

## **CONCLUSION**

The analyses show strong evidence of reliability and validity for the ASCQ-Me to be used as a measure of disease-specific HRQoL in SCD in the UK, replicating some of the findings of the US ACSQ-Me. The UK measure will be a valuable tool for assessing the HRQoL of adults with SCD, providing a useful outcome measure in both research and clinical practice.

## LIST OF ABBREVIATIONS

ACSQ-Me	Adult Sickle Cell Quality of Life Measurement Information System
AIMS	Arthritis Impact Measurement Scale
ANOVA	Analysis of variance
AVN	Avascular necrosis of hip
CFA	Confirmatory factor analysis
CFI	Comparative fit index
EQ-5D	EuroQol five-dimensional questionnaire
HADS	Hospital Anxiety & Depression Scale
HbSC	Haemoglobin SC
HbSS	Haemoglobin SS
HRQoL	Health-related quality of life
MCAR	Little's Missing Completely At Random
MCS	Mental component score
NRES	National Research Ethics Service
PCS	Physical component score
RMSEA	Root mean square error of approximation
S $\beta$ Thal	Haemoglobin S $\beta$ -thalassemia Hb
SCD	Sickle cell disease
SIMS	Sickle Cell Impact Measurement Scale
SF-36	RAND Medical Outcome Survey Short Form 36
TIA	Transient ischemic attack
TR	Elevated tricuspid regurgitation

VNS

Visual numeric scales

## **DECLARATIONS**

### *Ethics approval and consent to participate*

Ethical approval was granted from the National Research Ethics Service (NRES) Committee North West - Greater Manchester East, reference 14/NW/1522. All data were anonymised and stored securely. All participants were given a participant information sheet and informed consent to complete before they agreed to participate in the study.

### *Consent for publication*

Not applicable

### *Availability of data and material*

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

### *Competing interests*

The authors declare that they have no competing interests

### *Funding*

The study was not funded.

### *Authors' contributions*

KM, HM, PT, and ST designed the research study, KM collected the data, OC analysed the data and produced a first draft of the manuscript. All authors interpreted the data, revised the manuscript and approved the final submitted version.

### *Acknowledgements*

We wish to thank Karen Madgwick, Bernadette Hylton, Sophie Clay and Reesha Solanki, who assisted with data collection.



## REFERENCES

1. Streetly A, Latinovic R, Henthorn J: **Positive screening and carrier results for the England-wide universal newborn sickle cell screening programme by ethnicity and area for 2005–07.** *Journal of Clinical Pathology* 2010, **63**:626-629.
2. NICE CfCPa: **Sickle Cell Acute Painful Episode: Management of an Acute Painful Sickle Cell Episode in Hospital.** 2012.
3. Lucas: *A Sickle Crisis?: A Report of the National Confidential Enquiry Into Patient Outcome and Death.* NCEPOD; 2008.
4. Anie KA, Steptoe A, Bevan DH: **Sickle cell disease: Pain, coping and quality of life in a study of adults in the UK.** *British Journal of Health Psychology* 2002, **7**:331-344.
5. Panepinto JA: **Health-related quality of life in patients with hemoglobinopathies.** *ASH Education Program Book* 2012, **2012**:284-289.
6. Panepinto JA, Bonner M: **Health-related quality of life in sickle cell disease: Past, present, and future.** *Pediatric blood & cancer* 2012, **59**:377-385.
7. Ware Jr JE, Sherbourne CD: **The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection.** *Medical care* 1992:473-483.
8. Group TE: **EuroQol-a new facility for the measurement of health-related quality of life.** *Health policy* 1990, **16**:199-208.
9. Bowling A: *Measuring health: a review of quality of life measurement scales.* Open University Press Milton Keynes; 1991.
10. Beattie D, Golledge J, Greenhalgh R, Davies A: **Quality of life assessment in vascular disease: towards a consensus.** *European journal of vascular and endovascular surgery* 1997, **13**:9-13.
11. Bowling A: *Research methods in health: investigating health and health services.* McGraw-Hill Education (UK); 2014.
12. Adams-Graves P, Lamar K, Johnson C, Corley P: **Development and validation of SIMS: An instrument for measuring quality of life of adults with sickle cell disease.** *American journal of hematology* 2008, **83**:558-562.
13. Werner EM, Treadwell M, Hassell K, Keller S, Levine R: **Sickle Cell Disease Health-Related Quality of Life Questionnaire Project.** *Am Soc Hematology*; 2006.
14. Treadwell MJ, Hassell K, Levine R, Keller S: **Adult sickle cell quality-of-life measurement information system (ASCQ-Me): conceptual model based on review of the literature and formative research.** *The Clinical journal of pain* 2014, **30**:902.
15. Meenan RF, Gertman PM, Mason JH: **Measuring health status in arthritis.** *Arthritis & Rheumatism* 1980, **23**:146-152.
16. Keller SD, Yang M, Treadwell MJ, Werner EM, Hassell KL: **Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks.** *Health and quality of life outcomes* 2014, **12**:125.
17. Keller S, Yang M, Treadwell MJ, Hassell KL: **Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS® to ASCQ-Me<sup>sm</sup>.** *Health and quality of life outcomes* 2017, **15**:117.
18. Fries JF, Bruce B, Cella D: **The promise of PROMIS: using item response theory to improve assessment of patient-reported outcomes.** *Clinical and experimental rheumatology* 2005, **23**:S53.
19. Hofstede G: **The cultural relativity of the quality of life concept.** *Academy of Management review* 1984, **9**:389-398.
20. Alonso J, Bartlett SJ, Rose M, Aaronson NK, Chaplin JE, Efficace F, Leplège A, Aiping L, Tulskey DS, Raat H: **The case for an international patient-reported outcomes measurement information system (PROMIS®) initiative.** *Health and quality of life outcomes* 2013, **11**:210.

21. Keller S, Evensen C, Yang M: **Adult Sickle Cell Quality of Life Measurement Information System: ASCQ Me User's Manual**. Bethesda, MD: National Heart, Lung and Blood Institute 2011.
22. Asnani, Reid M, Ali S, Lipps G, Williams-Green P: **Quality of life in patients with sickle cell disease in Jamaica: rural-urban differences**. *Rural Remote Health* 2008, **8**:890.
23. Zigmond AS, Snaith RP: **The hospital anxiety and depression scale**. *Acta psychiatrica scandinavica* 1983, **67**:361-370.
24. Johnston M, Pollard B, Hennessey P: **Construct validation of the hospital anxiety and depression scale with clinical populations**. *Journal of psychosomatic research* 2000, **48**:579-584.
25. Anie KA, Green J, Tata P, Fotopoulos CE, Oni L, Davies SC: **Self-help manual-assisted cognitive behavioural therapy for sickle cell disease**. *Behavioural and cognitive psychotherapy* 2002, **30**:451-458.
26. Ritter PL, González VM, Laurent DD, Lorig KR: **Measurement of pain using the visual numeric scale**. *The Journal of rheumatology* 2006, **33**:574-580.
27. Little RJ: **A test of missing completely at random for multivariate data with missing values**. *Journal of the American statistical Association* 1988, **83**:1198-1202.
28. George D, Mallery P: **SPSS for Windows step by step: A simple guide and reference, 11.0 atualização (4ª edição)**. Boston: Allyn & Bacon; 2003.
29. FDA: **Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims**. *Fed Regist* 2009, **74**:65132-65133.
30. Evans JD: *Straightforward statistics for the behavioral sciences*. Brooks/Cole; 1996.
31. Brown TA, Moore MT: **Confirmatory factor analysis**. *Handbook of structural equation modeling* 2012:361-379.
32. Cook KF, Kallen MA, Amtmann D: **Having a fit: impact of number of items and distribution of data on traditional criteria for assessing IRT's unidimensionality assumption**. *Quality of Life Research* 2009, **18**:447-460.
33. Pereira SAdS, Brener S, Cardoso CS, Proietti ABdFC: **Sickle Cell Disease: quality of life in patients with hemoglobin SS and SC disorders**. *Revista brasileira de hematologia e hemoterapia* 2013, **35**:325-331.
34. McClish DK, Penberthy LT, Bovbjerg VE, Roberts JD, Aisiku IP, Levenson JL, Roseff SD, Smith WR: **Health related quality of life in sickle cell patients: the PiSCES project**. *Health and Quality of Life Outcomes* 2005, **3**:50.
35. Ferrucci L, Baldasseroni S, Bandinelli S, De Alfieri W, Cartei A, Calvani D, Baldini A, Masotti G, Marchionni N: **Disease severity and health-related quality of life across different chronic conditions**. *Journal of the American Geriatrics Society* 2000, **48**:1490-1495.
36. Akinola N, Bolarinwa R, Faponle A: **The import of abdominal pain in adults with sickle cell disorder**. *West African journal of medicine* 2009, **28**.
37. Steinberg MH: **Predicting clinical severity in sickle cell anaemia**. *British journal of haematology* 2005, **129**:465-481.
38. Sebastiani P, Nolan VG, Baldwin CT, Abad-Grau MM, Wang L, Adewoye AH, McMahon LC, Farrer LA, Taylor JG, Kato GJ: **A network model to predict the risk of death in sickle cell disease**. *Blood* 2007, **110**:2727-2735.
39. Aisiku IP, Smith WR, McClish DK, Levenson JL, Penberthy LT, Roseff SD, Bovbjerg VE, Roberts JD: **Comparisons of high versus low emergency department utilizers in sickle cell disease**. *Annals of emergency medicine* 2009, **53**:587-593.
40. Wickwar S, McBain HB, Ezra DG, Hirani SP, Rose GE, Newman SP: **What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review**. *Thyroid* 2014, **24**:1407-1418.
41. Excellence NifHaC: **Sickle cell disease**. London: NICE 2014.

## TABLES

Table 1. Patient Socio-Demographic Characteristics (n=173)

<b>Variable</b>	
<b>Age years, mean (SD)</b>	36.1 (12.5)
<b>Gender, n (%)</b>	
	Female 100 (57.8)
	Male 69 (39.9)
	Undisclosed 4 (2.3)
<b>Ethnicity, n (%)</b>	
	Black or Black British – African 118 (68.2)
	Black or Black British – Caribbean 39 (22.5)
	Black or Black British – Other 4 (2.3)
	White and Black African 3 (1.7)
	Other Mixed 1 (0.6)
	White British 1 (0.6)
	Undisclosed 7 (4.0)
<b>Employment, n (%)</b>	
	Full time work 64 (37.0)
	Unemployed 42 (24.3)
	Part time work 24 (13.9)
	Other 16 (9.2)
	Student 15 (8.7)
	Full time homemaker 6 (3.5)
	Undisclosed 6 (3.5)
<b>Highest Educational Qualification, n (%)</b>	
	Degree / Equivalent 70 (40.5)
	A Level / Equivalent 36 (20.8)
	Post graduate 34 (19.7)
	GSCE / O level / Equivalent 25 (14.5)
	No formal qualifications 4 (2.3)
	Undisclosed 4 (2.3)

Table 2. Clinical Characteristics (n=173)

<b>Variable</b>	
<b>SCD Diagnosis, n (%)</b>	
HbSS	125 (72.3)
HbSC	36 (20.8)
Hb S $\beta$ Thal	7 (4.0)
Missing	5 (2.9)
<b>Medical History, n (%)</b>	
Avascular necrosis (AVN) of hip	39 (22.5)
Stroke or recurrent TIA	19 (11.0)
Priapism <sup>†</sup>	19 (26.0)
Severe, renal impairment: Requiring renal replacement treatment	11 (6.4)
History of Retinopathy with visual impairment	37 (21.4)
Elevated tricuspid regurgitation (TR) jet velocity	10 (5.8)
Catheter diagnosis of pulmonary hypertension	5 (2.9)
Recurrent ankle ulceration during past 2 years	14 (8.1)
Chronic Pain: Persistent pain on most days lasting more than 6 months	52 (30.1)
<b>Acute Chest Syndrome – Transfusion required during the past 2 years, mean (SD)</b>	0.7 (2.3)
<b>Pain Crises, n (%)</b>	
Had 3 or more hospital admissions with pain crises in the previous 12 months	13 (7.5)
Had 1 or more pain crises per month on average	126 (72.8)
Take 2 or more doses of opiate analgesia per week on average	92 (53.2)

<sup>†</sup> Percentage frequency calculated with male sample only



Table 3. Patient Reported Descriptive Data

<b>Variable</b>	
<b>Current Pain VNS, mean (SD)</b>	2.8 (2.9)
<b>Current Stiffness VNS, mean (SD)</b>	2.5 (2.8)
<b>Current Fatigue VNS, mean (SD)</b>	4.0 (3.0)
<b>HADS Anxiety, mean (SD)</b>	7.6 (4.4)
<b>HADS Anxiety Classifications, n (%)</b>	
Non-cases (score of 0 to 7)	90 (54%)
Possible cases (score of 8 to 10)	35 (21%)
Probable cases (score of 11 to 21)	43 (25%)
<b>HADS Depression, mean (SD)</b>	7.1 (4.06)
<b>HADS Depression Classifications, n (%)</b>	
Non-cases (score of 0 to 7)	97 (59%)
Possible cases (score of 8 to 10)	46 (28%)
Probable cases (score of 11 to 21)	21 (13%)
<b>SF-36 Physical Component Summary, mean (SD)*</b>	37.26 (10.93)
<b>SF-36 Mental Component Summary, mean (SD)*</b>	44.02 (12.16)
<b>ASCQ-Me: In the past 12 months, how many sickle cell pain attacks (crises) did you have? n (%)</b>	
I did not have a pain attack	20 (11.6)
0	11 (6.4)
1	20 (11.6)
2	22 (12.7)
3	21 (12.1)
4 or more	79 (45.7)
<b>ASCQ-Me: When was your last pain attack?, n (%)</b>	
I've never had a pain episode	6 (3.5)
I have one right now	6 (3.5)
Less than a week ago	22 (12.7)
1-4 weeks ago	9 (5.2)
1-6 months ago	33 (19.1)
7-11 months ago	45 (26.0)
1-5 years ago	26 (15.0)
More than 5 years ago	26 (15.0)

<b>Variable</b>	
<b>ASCQ-Me Patient rating of pain severity in last attack (0 to 10), mean (SD)</b>	7.17 (0.17)
<b>ASCQ-Me: How much did your last pain attack (crisis) interfere with your life? n (%)</b>	
I've never had a pain attack (crisis)	3 (2)
Not at all, I did everything I usually do	17 (10)
I had to cut down on some things I usually do	44 (25)
I could not do most things I usually do	41 (24)
I could not take care of myself and needed some help from family or friends	40 (23)
I could not take care of myself and needed constant care from family, friends, doctors, or nurses	28 (16)
<b>ASCQ-Me: About how long did your most recent pain attack (crisis) last?</b>	
I've never had a pain attack (crisis)	4 (2)
Less than 1 hour	8 (5)
1-12 hours	25 (15)
13-23 hours	7 (4)
1-3 days	47 (27)
4-6 days	38 (22)
1-2 weeks	28 (16)
More than 2 weeks	16 (9)
<b>ASCQ-Me Pain Item Bank (7 day recall), mean (SD)</b>	
How often did you have pain so bad that you could not do anything for a whole day?	3.27 (1.18)
How often did you have pain so bad that you could not get out of bed?	3.49 (1.20)
How often did you have very severe pain?	3.32 (1.17)
How often did you have pain so bad that you had to stop what you were doing?	3.18 (1.19)
How often did you have pain so bad that it was hard to finish what you were doing?	3.21 (1.18)
<b>ASCQ-Me Sleep Item Bank (7 day recall), mean (SD)</b>	
How often did you stay up most of the night because you could not fall asleep?	3.00 (1.89)
How often was it very easy for you to fall asleep?*	2.79 (1.13)
How often did you have a lot of trouble falling asleep?	3.06 (1.21)

Variable	
How often did you stay up all night because you could not fall asleep?	3.39 (1.17)
How often did you stay up half the night because you could not fall asleep?	3.16 (1.11)
<b>ASCQ-Me Stiffness Item Bank (7 day recall), mean (SD)</b>	
How often were your joints very stiff when you woke up?	3.11 (1.29)
How often were your joints very stiff during the day?	3.29 (1.21)
How often were your joints so stiff during the day that you could not move?	3.88 (1.03)
How often did you wake up so stiff that you could not move?	3.89 (1.17)
How often did it take you a very long time to get out of bed because of stiffness?	3.69 (1.20)
<b>ASCQ-Me Emotional Distress Item Bank (7 day recall), mean (SD)</b>	
How often did you feel completely hopeless because of your health?	3.27 (1.39)
How lonely did you feel because of your health problems?	3.31 (1.38)
How depressed were you about your health problems?	3.40 (1.40)
How much do you worry about getting sick?	2.71 (1.39)
How often were you very worried about needing to go to the hospital?	3.04 (1.42)
<b>ASCQ-Me Social Functioning Item Bank (30 day recall), mean (SD)</b>	
How much did you rely on others to take care of you because of your health?	3.24 (1.17)
How often did your health slow you down?	2.65 (1.21)
How often did your health make it hard for you to do things?	2.74 (1.14)
How often did your health keep you from going out?	2.92 (1.16)
How much did your health make it hard for you to do things with your friends?	2.87 (1.20)
<b>Standardised Total ASCQ-Me Item Bank, mean (SD)</b>	
Pain	47.20 (10.05)
Sleep	50.04 (7.86)
Stiffness	49.22 (9.67)
Emotional Distress	46.63 (10.39)
Social Functioning	46.44 (10.15)

\*Reverse scored

Table 4. Confirmatory Factor Analysis of the ASCQ-Me

Item	Standardised Regression Weight*
<b>Pain</b>	
How often did you have pain so bad that you could not do anything for a whole day?	0.91
How often did you have pain so bad that you could not get out of bed?	0.88
How often did you have very severe pain?	0.91
How often did you have pain so bad that you had to stop what you were doing?	0.92
How often did you have pain so bad that it was hard to finish what you were doing?	0.95
<b>Sleep</b>	
How often did you stay up most of the night because you could not fall asleep?	0.57
How often was it very easy for you to fall asleep?	<0.40
How often did you have a lot of trouble falling asleep?	0.87
How often did you stay up all night because you could not fall asleep?	0.90
How often did you stay up half the night because you could not fall asleep?	0.94
<b>Stiffness</b>	
How often were your joints very stiff when you woke up?	0.84
How often were your joints very stiff during the day?	0.80
How often were your joints so stiff during the day that you could not move?	0.87
How often did you wake up so stiff that you could not move?	0.90
How often did it take you a very long time to get out of bed because of stiffness?	0.90
<b>Emotional Distress</b>	
How often did you feel completely hopeless because of your health?	0.90
How lonely did you feel because of your health problems?	0.90
How depressed were you about your health problems?	0.86
How much do you worry about getting sick?	0.76
How often were you very worried about needing to go to the hospital?	0.76
<b>Social Functioning</b>	

Item	Standardised Regression Weight*
How much did you rely on others to take care of you because of your health?	0.76
How often did your health slow you down?	0.93
How often did your health make it hard for you to do things?	0.93
How often did your health keep you from going out?	0.83
How much did your health make it hard for you to do things with your friends?	0.84

\*The regression weight can be interpreted as the correlation between each item and its respective item bank

Table 5. ASCQ-Me Convergent Validity: Correlations with SF-36 & HADS

		<b>Pain</b>	<b>Sleep Impact</b>	<b>Stiffness</b>	<b>Emotional Impact</b>	<b>Social Impact</b>	<b>Pain Crisis Frequency</b>	<b>Pain Crisis Severity</b>
<b>SF-36 Physical</b>	r	0.52*	0.51*	0.51*	0.48*	0.65*	0.58*	0.39*
<b>Component Score</b>	n	160	164	168	165	169	171	170
<b>SF-36 Mental</b>	r	0.37*	0.46*	0.37*	0.68*	0.61*	0.35*	-0.34*
<b>Component Score</b>	n	160	164	168	165	169	171	170
<b>HADS Anxiety</b>	r	-0.24*	-0.38*	-0.35*	-0.66*	-0.55*	-0.31*	-0.23*
	n	160	163	165	163	167	168	167
<b>HADS Depression</b>	r	-0.35*	-0.37*	-0.34*	-0.64*	-0.58*	-0.35*	-0.27*
	n	154	158	161	159	162	164	163

\*Significant result (p<.01)

Table 6. ASCQ-Me Known Groups Validity

	SCD Diagnosis (ANOVA)				Hospital Admissions (T-test)								
	HbSS	HbSC	Hb SβThal	F(df), p	≥3 Hospital admissions in the previous 12 months	< 3 Hospital admissions in the previous 12 months	t(df), p						
<b>Pain Impact</b>	46.62	49.42	49.16	1.16 (2, 156), 0.316	39.42	48.09	2.79 (153), 0.006*						
<b>Stiffness Impact</b>	48.81	50.29	52.67	0.78 (2, 162), 0.460	41.64	50.23	3.17 (161), 0.002*						
<b>Sleep Impact</b>	49.63	51.21	50.57	0.56 (2, 159), 0.571	44.35	50.60	2.79 (159), 0.006*						
<b>Emotional Impact</b>	45.95	50.56	45.58	2.81 (2, 159), 0.63	36.15	47.83	4.12 (159), 0.000*						
<b>Social Impact</b>	45.56	50.52	45.460	3.47 (2, 164), 0.34	39.58	39.58	4.193 (19), 0.001*						

\*Significant result (p<.01)

Table S1. ASCQ-Me Medical History Differences

	Medical History - Avascular Necrosis of Hip			Medical History - Chronic pain: Persistent Pain Most Days Lasting More than 6 months			Stroke or recurrent transient ischemic attack		
	No	Yes	t(df), p	No	Yes	t(df), p	No	Yes	t(df), p
<b>Pain Impact</b>	48.31	43.94	2.23 (157), 0.023	49.78	41.55	5.66 (113), <0.001*	47.56	45.84	0.643 (156), 0.521
<b>Stiffness Impact</b>	50.54	45.49	3.33 (9), 0.001*	51.85	43.87	5.37 (165), <0.001*	49.74	46.55	1.359 (164), 0.176
<b>Sleep Impact</b>	50.64	47.84	1.62 (47), 0.112	51.85	45.78	4.82 (161), <0.001*	49.99	50.44	-0.231 (160), 0.818
<b>Emotional Impact</b>	47.52	44.60	1.54 (162), 0.125	49.15	41.75	4.53 (162), <0.001*	47.29	44.12	1.246 (161), 0.214
<b>Social Impact</b>	47.48	43.64	2.09 (166), 0.038	49.13	40.92	5.91 (134), <0.001*	46.99	44.44	1.015 (165), 0.311
	Priapism			Severe, renal impairment: Requiring renal replacement treatment			History of Retinopathy with visual impairment		
	No	Yes	t(df), p	No	Yes	t(df), p	No	Yes	t(df), p
<b>Pain Impact</b>	49.77	44.33	1.952 (66), 0.055	47.66	43.14	1.442 (157), 0.151	47.83	45.34	1.205 (157), 0.230
<b>Stiffness Impact</b>	51.21	45.93	2.012 (69), 0.048	49.78	43.45	2.137 (165), 0.034	50.05	46.96	2.039 (76), 0.045
<b>Sleep Impact</b>	52.04	49.58	1.182 (66), 0.242	50.19	47.40	1.088 (161), 0.278	50.22	49.24	0.634 (161), 0.527
<b>Emotional Impact</b>	49.23	46.58	0.955 (68), 0.343	47.21	41.75	1.720 (162), 0.087	47.09	45.98	0.573 (162), 0.567
<b>Social Impact</b>	49.48	45.40	1.416 (69), 0.161	46.99	40.84	1.964 (166), 0.051	47.01	45.09	1.017 (166), 0.311

\*Significant result (p<.01)



Table S1 (continued). ASCQ-Me Medical History Differences

	Catheter diagnosis of pulmonary hypertension			Recurrent ankle ulceration during past 2 years			Elevated tricuspid regurgitation (TR) jet velocity		
	No	Yes	t(df), p	No	Yes	t(df), p	No	Yes	t(df), p
<b>Pain Impact</b>	47.22	55.80	-1.69 (156), 0.092	47.60	44.78	1.000 (157), 0.319	47.41	44.40	0.871 (155), 0.385
<b>Stiffness Impact</b>	49.49	48.84	0.150 (164), 0.881	49.86	43.95	2.229 (165), 0.027	49.40	47.13	1.280 (14), 0.222
<b>Sleep Impact</b>	50.07	48.36	0.478 (161), 0.633	49.96	50.61	-0.292 (161), 0.770	50.02	49.58	0.169 (159), 0.866
<b>Emotional Impact</b>	47.10	42.90	0.909 (161), 0.365	46.93	45.89	0.362 (162), 0.718	47.00	42.64	1.313 (160), 0.191
<b>Social Impact</b>	46.86	41.92	1.084 (165), 0.280	46.78	44.55	0.786 (166), 0.433	46.39	48.80	-0.726 (164), 0.469

\*Significant result (p<.01)

Table S2. Current treatment. Descriptive statistics for treatments taken by two or more participants.

<b>Treatment</b>	<b>Number of participants currently taking treatment</b>
Antibiotic	137
Folic acid	129
Strong opioid	84
Moderate strength opioid	82
Paracetamol	57
Non-steroidal anti-inflammatory	46
Hydroxycarbamide	29
Vitamin D	28
Lansoprazole	11
Iron chelation	10
Amlodipine	7
Anticoagulation	6
Cyclizine	6
Omeprazole	6
Amitriptyline	5
Aspirin	5
Ramipril	5
Senna	5
Hydroxychloroquine	4
Calcium	3
Citalopram	3
Docusate sodium	3
Gabapentin	3
Phenoxyethylpenicillin	3

Prednisolone	3
Salbatamol	3
Alendronic acid	2
Azathioprine	2
Ceterizine tablets	2
Chlorophenamine	2
Etilefrine	2
Methotrexate	2
Perindopril	2
Pregablin	2
Propranolol	2
Seretide inhaler	2
Solpadol	2
Spirolactone	2
Sulfasalazine	2